



an Open Access Journal by MDPI

# Targeting Proline Metabolic Pathway for Regulation of Apoptosis/Autophagy in Cancer

Guest Editor:

#### Dr. Wojciech Miltyk

Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Białystok, Poland

Deadline for manuscript submissions: closed (25 November 2021)

### Message from the Guest Editor

Proline metabolism involves glutamate and ornithine, and enzymatic activity of proline oxidase,  $\Delta^1$ -pyrroline-5carboxylate (P5C) reductase, P5C dehydrogenase, P5C synthetase, and ornithine d-aminotransferase. The pathway is connected to other essential metabolic cycles: TCA, urea, and pentose phosphate pathway. Disorders in proline metabolism are linked to several diseases. Recent discoveries on the proline metabolism, enzymes involved in proline synthesis and catabolism indicate its important role in tumor growth and cancer progression.

This Special Issue aims to cover the cutting-edge research activities and recent advancements in the area of proline metabolism pathways and factors regulating its activity as a molecular target for cancer treatment.

I cordially invite you to publish your manuscripts in this *Pharmaceuticals* Special Issue, titled "Targeting Proline Metabolic Pathway for Regulation of Apoptosis/Autophagy in Cancer."









an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande,Edifício C8, 5° Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peerreviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

# **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

# **Contact Us**

*Pharmaceuticals* Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/pharmaceuticals pharmaceuticals@mdpi.com